The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
The clonal and mutational evolution spectrum of primary triple-negative breast cancers
Open accessAbstract
Primary triple-negative breast cancers (TNBCs), a tumour type defined by lack of oestrogen receptor, progesterone receptor and ERBB2 gene amplification, represent approximately 16% of all breast cancers. Here we show in 104 TNBC cases that at the time of diagnosis these cancers exhibit a wide and continuous spectrum of genomic evolution, with some having only a handful of coding somatic aberrations in a few pathways, whereas others contain hundreds of coding somatic mutations. High-throughput RNA sequencing (RNA-seq) revealed that only approximately 36% of mutations are expressed. Using deep re-sequencing measurements of allelic abundance for 2,414 somatic mutations, we determine for the first time-to our knowledge-in an epithelial tumour subtype, the relative abundance of clonal frequencies among cases representative of the population. We show that TNBCs vary widely in their clonal frequencies at the time of diagnosis, with the basal subtype of TNBC showing more variation than non-basal TNBC. Although p53 (also known as TP53), PIK3CA and PTEN somatic mutations seem to be clonally dominant compared to other genes, in some tumours their clonal frequencies are incompatible with founder status. Mutations in cytoskeletal, cell shape and motility proteins occurred at lower clonal frequencies, suggesting that they occurred later during tumour progression. Taken together, our results show that understanding the biology and therapeutic responses of patients with TNBC will require the determination of individual tumour clonal genotypes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It is estimated that p53 is mutated in approximately 50% of all cancers with 60% of TNBCs bearing mutations in p53 (14, 15);”
From Potentiation of carboplatin-mediated DNA damage by the Mdm2 modulator Nutlin-3a in a humanized orthotopic breast-to-lung metastatic model (2015) · cites this paper as [15]
In the citing paper
“It is estimated that p53 is mutated in approximately 50% of all cancers with 60% of TNBCs bearing mutations in p53 (14, 15);”
From Potentiation of carboplatin-mediated DNA damage by the Mdm2 modulator Nutlin-3a in a humanized orthotopic breast-to-lung metastatic model (2015) · cites this paper as [15]
In the citing paper
“Approximately 60% of basal TNBCs bear mutations in p53 (15) and ~90% of mutations in p53 occur in the DNA binding domain.”
From Potentiation of carboplatin-mediated DNA damage by the Mdm2 modulator Nutlin-3a in a humanized orthotopic breast-to-lung metastatic model (2015) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C., Sørlie, T., Eisen, M., van de Rijn, M., Jeffrey, S., Rees, C. A., Pollack, J., Ross, D., Johnsen, H., Akslen, L., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,551
Sørlie, T., Perou, C. M., Tibshirani, R. J., Aas, T., Geisler, S. B., Johnsen, H., Hastie, T. J., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 11,506
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,927
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097
Self-citationSupervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S. C. Y., Voduc, D. K., Vickery, T. L., Davies, S. R., Fauron, C. M. ‐., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,818
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
The Mutational Landscape of Head and Neck Squamous Cell Carcinoma
Stransky, N., Egloff, A. M., Tward, A. D., Kostic, A. D., Cibulskis, K., Sivachenko, A., Kryukov, G. V., Lawrence, M. S., Sougnez, C. L., McKenna, A., et al. (2011) · Science · doi:10.1126/science.1208130 · Cited by 2,541
Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1
Agrawal, N., Frederick, M. J., Pickering, C. R., Bettegowda, C., Chang, K., Li, R. J., Fakhry, C., Xie, T., Zhang, J., Wang, J., et al. (2011) · Science · doi:10.1126/science.1206923 · Cited by 1,697
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma
Morin, R. D., Mendez-Lago, M., Mungall, A. J., Goya, R., Mungall, K. L., Corbett, R. D., Johnson, N. A., Severson, T. M., Chiu, R., Field, M., et al. (2011) · Nature · doi:10.1038/nature10351 · Cited by 1,614
Self-citationGenome remodelling in a basal-like breast cancer metastasis and xenograft
Ding, L., Ellis, M. J., Li, S., Larson, D. E., Chen, K., Wallis, J. W., Harris, C. C., McLellan, M. D., Fulton, R. S., Fulton, L., et al. (2010) · Nature · doi:10.1038/nature08989 · Cited by 1,144
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–400 of 1,003
A framework for clinical cancer subtyping from nucleosome profiling of cell-free DNA
Doebley, A.-L., Ko, M., Liao, H., Cruikshank, A. E., Santos, K., Kikawa, C., Hiatt, J. B., Patton, R. D., Sarkar, N. D., Collier, K. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-35076-w · Cited by 135
Self-citationDai, M., Yan, G., Wang, N., Daliah, G., Edick, A. M., Poulet, S., Boudreault, J., Ali, S., Burgos, S. A., & Lebrun, J. J. (2021) · Nature Communications · doi:10.1038/s41467-021-23316-4 · Cited by 130
Biological Subtypes of Triple-Negative Breast Cancer
Hubalek, M., Czech, T., & Müller, H. M. (2017) · Breast Care · doi:10.1159/000455820 · Cited by 128
Zhang, J., Späth, S. S., Marjani, S. L., Zhang, W., & Pan, X. (2018) · Precision Clinical Medicine · doi:10.1093/pcmedi/pby007 · Cited by 137
Zhao, Y., Li, Z., Zhu, Y., Fu, J., Zhao, X., Zhang, Y., Wang, S., Wu, J., Wang, K., Wu, R. T., et al. (2021) · Advanced Science · doi:10.1002/advs.202003897 · Cited by 130
Self-citationChen, D., Bhat‐Nakshatri, P., Goswami, C. P., Badve, S., & Nakshatri, H. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1080 · Cited by 130
iReckon: Simultaneous isoform discovery and abundance estimation from RNA-seq dataPreprint
Mezlini, A. M., Smith, E. J. M., Fiume, M., Buske, O., Savich, G. L., Shah, S., Aparicio, S. A. J. R., Chiang, D. Y., Goldenberg, A., & Brudno, M. (2012) · Genome Research · doi:10.1101/gr.142232.112 · Cited by 128
Self-citationZeng, L., & Yang, K. (2017) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2017.01.045 · Cited by 129
TrAp: a tree approach for fingerprinting subclonal tumor composition
Strino, F., Parisi, F., Micsinai, M., & Kluger, Y. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt641 · Cited by 126
The mutational landscape of chromatin regulatory factors across 4,623 tumor samples
González-Pérez, A., Jené-Sanz, A., & López-Bigas, N. (2013) · Genome biology · doi:10.1186/gb-2013-14-9-r106 · Cited by 131
Next generation sequencing in cancer research and clinical application
Shyr, D., & Liu, Q. (2013) · Biological Procedures Online · doi:10.1186/1480-9222-15-4 · Cited by 130
Adams, C. M., Mitra, R., Xiao, Y., Michener, P., Palazzo, J., Chao, A., Gour, J., Cassel, J. A., Salvino, J. M., & Eischen, C. M. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1131 · Cited by 126
Epithelial-to-Mesenchymal Transition Rewires the Molecular Path to PI3K-Dependent Proliferation
Salt, M. B., Bandyopadhyay, S., & McCormick, F. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0520 · Cited by 124
Clinical implications of molecular heterogeneity in triple negative breast cancer
Lehmann, B. D., & Pietenpol, J. A. (2015) · The Breast · doi:10.1016/j.breast.2015.07.009 · Cited by 124
Targeting triple negative breast cancer: Is p53 the answer?
Turner, N. H., Moretti, E., Siclari, O., Migliaccio, I., Santarpia, L., D’Incalci, M., Piccolo, S., Veronesi, A., Zambelli, A., Sal, G. D., et al. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.12.001 · Cited by 124
Khosravi‐Shahi, P., Cabezón‐Gutiérrez, L., & Custodio‐Cabello, S. (2017) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12748 · Cited by 130
Cell‐free circulating tumour DNA as a liquid biopsy in breast cancer
Mattos‐Arruda, L. D., & Caldas, C. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.12.001 · Cited by 124
Self-citationGenetic Heterogeneity, Tumor Microenvironment and Immunotherapy in Triple-Negative Breast Cancer
Kúdelová, E., Smolár, M., Holubeková, V., Horňáková, A., Dvorská, D., Lučanský, V., Koklesová, L., Kúdela, E., & Kubatka, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314937 · Cited by 127
Molecular Regulation Mechanisms and Interactions Between Reactive Oxygen Species and Mitophagy
Fan, P., Xie, X.-H., Chen, C., Peng, X., Zhang, P., Yang, C. H., & Wang, Y. (2018) · DNA and Cell Biology · doi:10.1089/dna.2018.4348 · Cited by 122
Drugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer
Alves, C. L., & Ditzel, H. J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054522 · Cited by 126
Targeting Different Pathways Using Novel Combination Therapy in Triple Negative Breast Cancer
Mir, M. A., Qayoom, H., Mehraj, U., Nisar, S., Bhat, B. A., & Wani, N. A. (2020) · Current Cancer Drug Targets · doi:10.2174/1570163817666200518081955 · Cited by 118
Nanotechnology-based siRNA delivery strategies for treatment of triple negative breast cancer
Chadar, R., Afsana, & Kesharwani, P. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120835 · Cited by 123
The Mitochondrial and Autosomal Mutation Landscapes of Prostate Cancer
Lindberg, J., Mills, I. G., Klevebring, D., Liu, W., Neiman, M., Xu, J., Wikström, P., Wiklund, P. N., Wiklund, F. E., Egevad, L., et al. (2012) · European Urology · doi:10.1016/j.eururo.2012.11.053 · Cited by 117
Going with the Flow: From Circulating Tumor Cells to DNA
Bidard, F., Weigelt, B., & Reis-Filho, J. S. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006305 · Cited by 123
Guerrab, A. E., Bamdad, M., Kwiatkowski, F., Bignon, Y., Penault-Llorca, F. M., & Aubel, C. (2016) · Oncotarget · doi:10.18632/oncotarget.12037 · Cited by 120
Pitt, J. J., Riester, M., Zheng, Y., Yoshimatsu, T. F., Sanni, A., Oluwasola, O., Veloso, A., Labrot, E., Wang, S., Odetunde, A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06616-0 · Cited by 123
Tumor mutational burden as a predictor of immunotherapy response in breast cancer
O’Meara, T. A., & Tolaney, S. M. (2021) · Oncotarget · doi:10.18632/oncotarget.27877 · Cited by 122
CLK2 Is an Oncogenic Kinase and Splicing Regulator in Breast Cancer
Yoshida, T., Kim, J. H., Carver, K. C., Su, Y., Weremowicz, S., Mulvey, L. A., Yamamoto, S., Brennan, C. W., Mei, S., Long, H. W., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2443 · Cited by 120
Oncogenic miR-181a/b affect the DNA damage response in aggressive breast cancer
Bisso, A., Faleschini, M., Zampa, F., Capaci, V., Santa, J. D., Santarpia, L., Piazza, S., Cappelletti, V., Daidone, M. G., Agami, R., et al. (2013) · Cell Cycle · doi:10.4161/cc.24757 · Cited by 120
Genomic Medicine Frontier in Human Solid Tumors: Prospects and Challenges
Dienstmann, R., Rodon, J. A., Barretina, J., & Tabernero, J. M. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2268 · Cited by 120
Therapeutic landscape in mutational triple negative breast cancer
Shi, Y., Jin, J., Ji, W., & Guan, X. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0850-9 · Cited by 118
Mediator kinase module and human tumorigenesis
Clark, A. D., Oldenbroek, M., & Boyer, T. (2015) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2015.1064854 · Cited by 121
Tumor-infiltrating lymphocytes in breast cancer according to tumor subtype: Current state of the art
Solinas, C., Carbognin, L., Silva, P. D., Criscitiello, C., & Lambertini, M. (2017) · The Breast · doi:10.1016/j.breast.2017.07.005 · Cited by 116
Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition
Chen, X., Low, K.-H., Alexander, A., Jiang, Y., Karakaş, C., Hess, K. R., Carey, J. P. W., Bui, T. N., Vijayaraghavan, S., Evans, K. W., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1446 · Cited by 118
KLF6-SV1 Drives Breast Cancer Metastasis and Is Associated with Poor Survival
Hatami, R., Sieuwerts, A. M., Izadmehr, S., Yao, Z., Qiao, R., Papa, L., Look, M. P., Smid, M., Ohlseen, J., Levine, A. C., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3004688 · Cited by 117
Weisman, P. S., Ng, C. K. Y., Brogi, E., Eisenberg, R. E. K., Won, H. H., Piscuoglio, S., Filippo, M. R. D., Ioris, R. A., Akram, M. M., Norton, L., et al. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.39 · Cited by 115
The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer
Mattos‐Arruda, L. D., Sammut, S., Ross, E. M., Bashford-Rogers, R. J. M., Greenstein, E., Markus, H., Morganella, S., Teng, Y. H. F., Maruvka, Y. E., Pereira, B., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.04.098 · Cited by 117
Self-citationManjunath, M., & Choudhary, B. (2021) · Oncology Letters · doi:10.3892/ol.2021.12773 · Cited by 123
Bassiouni, R., Idowu, M. O., Gibbs, L. D., Robila, V., Grizzard, P. J., Webb, M. G., Song, J., Noriega, A., Craig, D. W., & Carpten, J. D. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-2682 · Cited by 119
Zafar, H., Navin, N. E., Chen, K., & Nakhleh, L. K. (2019) · Genome Research · doi:10.1101/gr.243121.118 · Cited by 113
Classical pathology and mutational load of breast cancer – integration of two worlds
Budczies, J., Bockmayr, M. L., Denkert, C., Klauschen, F., Lennerz, J. K., Győrffy, B., Dietel, M., Loibl, S., Weichert, W., & Stenzinger, A. (2015) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.25 · Cited by 114
Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics
Collins, D. C., Sundar, R., Lim, J. S. J., & Yap, T. A. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.10.012 · Cited by 116
Stieber, D., Golebiewska, A., Evers, L., Lenkiewicz, E., Brons, N. H. C., Nicot, N., Oudin, A., Bougnaud, S., Hertel, F., Bjerkvig, R., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1196-4 · Cited by 112
Mutant p53: a novel target for the treatment of patients with triple‐negative breast cancer?
Synnott, N. C., Murray, A., McGowan, P. M., Kiely, M., Kiely, P. A., O’Donovan, N., O’Connor, D. P., Gallagher, W. M., Crown, J. P., & Duffy, M. J. (2016) · International Journal of Cancer · doi:10.1002/ijc.30425 · Cited by 112
Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status
Keung, M. Y., Wu, Y., Badar, F., & Vadgama, J. V. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9040940 · Cited by 115
Ma, C. X., Ellis, M. J., Petroni, G. R., Guo, Z., Cai, S.-R., Ryan, C. E., Lockhart, A. C., Naughton, M. J., Pluard, T., Brenin, C. M., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2378-9 · Cited by 111
Yam, C., Mani, S. A., & Moulder, S. L. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0095 · Cited by 116
Understanding mutagenesis through delineation of mutational signatures in human cancer
Petljak, M., & Alexandrov, L. B. (2016) · Carcinogenesis · doi:10.1093/carcin/bgw055 · Cited by 110
Natrajan, R., Wilkerson, P. M., Marchiò, C., Piscuoglio, S., Ng, C. K. Y., Wai, P. T., Lambros, M. B. K., Samartzis, E. P., Dedes, K. J., Frankum, J. R., et al. (2014) · The Journal of Pathology · doi:10.1002/path.4325 · Cited by 110
An emerging role of PARK2 in cancer
Xu, L., Lin, D., Yin, D., & Koeffler, H. P. (2013) · Journal of Molecular Medicine · doi:10.1007/s00109-013-1107-0 · Cited by 114
Liu, J. C., Voisin, V., Wang, S., Wang, D., Jones, R. A., Datti, A., Uehling, D., Al‐awar, R., Egan, S. E., Bader, G. D., et al. (2014) · EMBO Molecular Medicine · doi:10.15252/emmm.201404402 · Cited by 110
The translational challenges of precision oncology
Pich, O., Bailey, C., Watkins, T. B. K., Zaccaria, S., Jamal‐Hanjani, M., & Swanton, C. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.04.002 · Cited by 116
Inferring Clonal Composition from Multiple Sections of a Breast Cancer
Zare, H., Wang, J., Hu, A. K., Weber, K., Smith, J., Nickerson, D. A., Song, C.-Z., Witten, D., Blau, C. A., & Noble, W. S. (2014) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003703 · Cited by 103
Hajirasouliha, I., Mahmoody, A., & Raphael, B. J. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu284 · Cited by 106
Intratumoral heterogeneity and drug resistance in cancer
Fu, Y.-C., Liang, S.-B., Luo, M., & Wang, X. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03734-w · Cited by 129
Genome evolution during progression to breast cancerPreprint
Newburger, D. E., Kashef-Haghighi, D., Weng, Z., Salari, R., Sweeney, R. T., Brunner, A. L., Zhu, S., Guo, X., Varma, S., Troxell, M. L., et al. (2013) · Genome Research · doi:10.1101/gr.151670.112 · Cited by 108
Laskin, J. J., Jones, S. J. M., Aparicio, S. A. J. R., Chia, S., Ch’ng, C., Deyell, R. J., Eirew, P. D., Fok, A. K., Gelmon, K. A., Ho, C., et al. (2015) · Molecular Case Studies · doi:10.1101/mcs.a000570 · Cited by 109
Self-citationTriple-Negative Breast Cancer: Immune Modulation as the New Treatment Paradigm
Disis, M. L., & Stanton, S. E. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.e25 · Cited by 108
Cancer in Light of Experimental Evolution
Sprouffske, K., Merlo, L. M. F., Gerrish, P. J., Maley, C. C., & Sniegowski, P. (2012) · Current Biology · doi:10.1016/j.cub.2012.06.065 · Cited by 110
Mutant p53: Multiple Mechanisms Define Biologic Activity in Cancer
Kim, M., Zhang, Y., & Lozano, G. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00249 · Cited by 113
Breast cancer survival among young women: a review of the role of modifiable lifestyle factors
Brenner, D. R., Brockton, N. T., Kotsopoulos, J., Cotterchio, M., Boucher, B. A., Courneya, K. S., Knight, J. A., Olivotto, I. A., Quan, M. L., & Friedenreich, C. M. (2016) · Cancer Causes & Control · doi:10.1007/s10552-016-0726-5 · Cited by 119
Morris, Q., Liu, P., Woloszynska‐Read, A., Zhang, J., Luo, W. F., Qin, M., Bshara, W., Conroy, J. M., Sabatini, L. M., Vedell, P. T., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1313580111 · Cited by 107
Nguyen, L. V., Cox, C. L., Eirew, P. D., Knapp, D. J. H. F., Pellacani, D., Kannan, N., Carles, A., Moksa, M., Balani, S., Shah, S. P., et al. (2014) · Nature Communications · doi:10.1038/ncomms6871 · Cited by 107
Self-citationProtein biomarkers for subtyping breast cancer and implications for future research
Mueller, C., Haymond, A. N., Davis, J. B., Williams, A. W., & Espina, V. A. (2017) · Expert Review of Proteomics · doi:10.1080/14789450.2018.1421071 · Cited by 110
Bhatia, S., Kramer, M., Russo, S., Naik, P., Arun, G., Brophy, K., Andrews, P., Fan, C., Perou, C. M., Preall, J. B., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-2807 · Cited by 103
Beckman, R. A., Schemmann, G. S., & Yeang, C. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203559109 · Cited by 106
Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer
Cossu‐Rocca, P., Orrù, S., Muroni, M. R., Sanges, F., Sotgiu, G., Ena, S., Pira, G., Murgia, L., Manca, A., Uras, M. G., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0141763 · Cited by 104
Masui, K., Gini, B., Wykosky, J., Zanca, C., Mischel, P. S., Furnari, F. B., & Cavenee, W. K. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt086 · Cited by 111
Mitophagy in the pathogenesis and management of disease
Wang, Q., Sun, Y., Li, T. Y., & Auwerx, J. (2026) · Cell Research · doi:10.1038/s41422-025-01203-7 · Cited by 103
Cancer genome-sequencing study design
Mwenifumbo, J. C., & Marra, M. A. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3445 · Cited by 104
Self-citationYeong, J. P.-S., Lim, J. C. T., Lee, B. T. K., Li, H., Ong, C. C. H., Thike, A. A., Yeap, W. H., Yang, Y. L., Lim, A. Y. H., Tay, T. K. Y., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0499-y · Cited by 104
Salemme, V., Centonze, G., Avalle, L., Natalini, D., Piccolantonio, A., Arina, P., Morellato, A., Ala, U., Taverna, D., Turco, E., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1170264 · Cited by 106
Singel, S. M., Cornelius, C., Zaganjor, E., Batten, K. G., Sarode, V. R., Buckley, D. L., Peng, Y. S., John, G. B., Li, H. C., Sadeghi, N., et al. (2014) · Neoplasia · doi:10.1016/j.neo.2014.03.008 · Cited by 104
A Cancer Theory Kerfuffle Can Lead to New Lines of Research
Baker, S. G. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju405 · Cited by 107
Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers
Mauro, C. D., Rosa, R., D'Amato, V., Ciciola, P., Servetto, A., Marciano, R., Orsini, R. C., Formisano, L., Falco, S. D., Cicatiello, V., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.116 · Cited by 101
Fan, Y., Zhou, X. Y., Xia, T., Chen, Z., Li, J., Liu, Q., Alolga, R. N., Chen, Y., Lai, M., Li, P., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7155 · Cited by 104
Hurvitz, S. A., & Mead, M. D. (2015) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000239 · Cited by 100
Adjuvant and Neoadjuvant Treatment of Triple-Negative Breast Cancer With Chemotherapy
Marra, A., & Curigliano, G. (2021) · The Cancer Journal · doi:10.1097/ppo.0000000000000498 · Cited by 102
Sapino, A., Goia, M., Recupero, D., & Marchiò, C. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00129 · Cited by 100
Therapies for triple negative breast cancer
Andreopoulou, E., Schweber, S. J., Sparano, J. A., & McDaid, H. M. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1032246 · Cited by 102
Understanding genomic alterations in cancer genomes using an integrative network approach
Wang, E. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.11.050 · Cited by 100
Clonal evolution of high‐grade serous ovarian carcinoma from primary to recurrent disease
Castellarin, M. L., Milne, K., Zeng, T., Tse, K., Mayo, M., Zhao, Y., Webb, J. R., Watson, P. H., Nelson, B. H., & Holt, R. A. (2012) · The Journal of Pathology · doi:10.1002/path.4105 · Cited by 101
Self-citationClinical Actionability Enhanced through Deep Targeted Sequencing of Solid Tumors
Chen, K., Meric‐Bernstam, F., Zhao, H., Zhang, Q. C., Ezzeddine, N., Tang, L.-Y., Qi, Y., Mao, Y., Chen, T., Chong, Z., et al. (2015) · Clinical Chemistry · doi:10.1373/clinchem.2014.231100 · Cited by 97
Metabolomics Applications in Precision Medicine: An Oncological Perspective
Puchades‐Carrasco, L., & Pineda‐Lucena, A. (2017) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026617666170707120034 · Cited by 101
Theranostics of Triple-Negative Breast Cancer Based on Conjugated Polymer Nanoparticles
Jin, G., He, R., Liu, Q., Dong, Y., Lin, M., Li, W., & Xu, F. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b14603 · Cited by 99
Sundqvist, A., Vasilaki, E., Voytyuk, O., Bai, Y., Morikawa, M., Moustakas, A., Miyazono, K., Heldin, C., ten Dijke, P., & van Dam, H. (2020) · Oncogene · doi:10.1038/s41388-020-1299-z · Cited by 100
Millis, S. Z., Gatalica, Z., Winkler, J., Vranić, S., Kimbrough, J., Reddy, S. K., & O’Shaughnessy, J. (2015) · Clinical Breast Cancer · doi:10.1016/j.clbc.2015.04.008 · Cited by 97
Beltrán, A. S., Graves, L. M., & Blancafort, P. (2013) · Oncogene · doi:10.1038/onc.2013.422 · Cited by 95
Clinical applications of next generation sequencing in cancer: from panels, to exomes, to genomes
Shen, T. S., der Stadt, S. P.-V., Yeat, N. C., & Lin, J. (2015) · Frontiers in Genetics · doi:10.3389/fgene.2015.00215 · Cited by 97
Next-generation sequencing in breast cancer
Desmedt, C., Voet, T., Sotiriou, C. P., & Campbell, P. J. (2012) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328359554e · Cited by 96
Garmpis, N., Damaskos, C., Garmpi, A., Kalampokas, E., Kalampokas, T., Spartalis, E. D., Daskalopoulou, A., Valsami, S. I., Kontos, M. C., Nonni, A., et al. (2017) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20041 · Cited by 96
Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study Network
Fasching, P. A., Brucker, S. Y., Fehm, T. N., Overkamp, F., Janni, W., Wallwiener, M., Hadji, P., Belleville, E., Häberle, L., Taran, F., et al. (2015) · Geburtshilfe und Frauenheilkunde · doi:10.1055/s-0034-1396215 · Cited by 93
Hoadley, K. A., Siegel, M. B., Kanchi, K., Miller, C. A., Ding, L., Wei, Z., He, X., Parker, J. S., Wendl, M. C., Fulton, R. S., et al. (2016) · PLoS Medicine · doi:10.1371/journal.pmed.1002174 · Cited by 97
Zhang, F.-L., Cao, J.-L., Xie, H.-Y., Sun, R., Yang, L.-F., Shao, Z., & Li, D. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-1394 · Cited by 99
Leveraging the complementary nature of RNA‐Seq and shotgun proteomics data
Wang, X., Liu, Q., & Zhang, B. (2014) · PROTEOMICS · doi:10.1002/pmic.201400184 · Cited by 95
Niepel, M., Hafner, M. A., Pace, E. A., Chung, M., Chai, D. H., Zhou, L., Schoeberl, B., & Sorger, P. K. (2013) · Science Signaling · doi:10.1126/scisignal.2004379 · Cited by 93
Ku, C., & Roukos, D. H. (2013) · Expert Review of Medical Devices · doi:10.1586/erd.12.63 · Cited by 95
A dried blood spot mass spectrometry metabolomic approach for rapid breast cancer detection
Cao, Y., Wang, Q., Gao, P., Dong, J., Zhu, Z., Fang, Y., Fang, Z., Sun, X., & Sun, T. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s95862 · Cited by 96
Lamy, P., Nordentoft, I., Birkenkamp‐Demtröder, K., Thomsen, M. B. H., Villesen, P., Vang, S., Hedegaard, J., Borre, M., Jensen, J. B., Høyer, S., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0436 · Cited by 93
Shrivastava, S., Jeengar, M. K., Thummuri, D., Koval, A., Katanaev, V. L., Marepally, S. K., & Naidu, V. G. M. (2016) · BioFactors · doi:10.1002/biof.1315 · Cited by 94
Metadata
- Authors
- Shah, S. P., Roth, A., Goya, R., Oloumi, A., Ha, G., Zhao, Y., Turashvili, G., Ding, J., Tse, K., Haffari, G., Bashashati, A., Prentice, L. M., Khattra, J., Burleigh, A., Yap, D., Bernard, V., McPherson, A., Shumansky, K., Crisan, A., Giuliany, R., Heravi-Moussavi, A., Rosner, J., Lai, D., Birol, I., Varhol, R., Tam, A., Dhalla, N., Zeng, T., Ma, K., Chan, S. K., Griffith, M., Moradian, A., Cheng, S.-W. G., Morin, G. B., Watson, P., Gelmon, K., Chia, S., Chin, S.-F., Curtis, C., Rueda, O. M., Pharoah, P. D., Damaraju, S., Mackey, J., Hoon, K., Harkins, T., Tadigotla, V., Sigaroudinia, M., Gascard, P., Tlsty, T., Costello, J. F., Meyer, I. M., Eaves, C. J., Wasserman, W. W., Jones, S., Huntsman, D., Hirst, M., Caldas, C., Marra, M. A., & Aparicio, S.
- Affiliations
- University of British Columbia (CA)
- Canada's Michael Smith Genome Sciences Centre (CA)
- BC Cancer Agency (CA)
- University of Cambridge (GB)
- University of Southern California (US)
- Cancer Research UK (GB)
- University of Alberta (CA)
- University of California, San Francisco (US)
- Corresponding author
- Shah, Sohrab P.
- Caldas, Carlos
- Marra, Marco A.
- Aparicio, Samuel
- ORCID
- Shah, Sohrab P.
- Roth, Andrew
- Ha, Gavin
- Zhao, Yongjun
- Turashvili, Gulisa
- Ding, Jiarui
- Haffari, Gholamreza
- Bashashati, Ali
- Prentice, Leah M.
- Burleigh, Angela
- Yap, Damian
- McPherson, Andrew
- Crisan, Anamaria
- Rosner, Jamie
- Lai, Daniel
- Varhol, Richard
- Tam, Angela
- Griffith, Malachi
- Moradian, Annie
- Cheng, S.-W. Grace
- Morin, Gregg B.
- Watson, Peter
- Gelmon, Karen
- Chia, Stephen
- Chin, Suet-Feung
- Curtis, Christina
- Rueda, Oscar M.
- Pharoah, Paul D.
- Damaraju, Sambasivarao
- Mackey, John
- Harkins, Timothy
- Gascard, Philippe
- Tlsty, Thea
- Costello, Joseph F.
- Meyer, Irmtraud M.
- Eaves, Connie J.
- Wasserman, Wyeth W.
- Jones, Steven
- Huntsman, David
- Hirst, Martin
- Caldas, Carlos
- Marra, Marco A.
- Aparicio, Samuel
- Venue
- Nature
- Published
- 2012-04-04
- Volume
- 486
- Issue
- 7403
- Pages
- 395-399
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3863681
- OpenAlex
- W2063382533
- Cited by
- 1,967
- References
- 23
- Citations by year
- 2026: 40 · 2025: 61 · 2024: 71 · 2023: 131 · 2022: 132 · 2021: 119 · 2020: 131 · 2019: 120 · 2018: 135 · 2017: 173 · 2016: 179 · 2015: 198 · 2014: 199 · 2013: 201 · 2012: 76
- FWCI
- 71.57
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- MDC Repository (Max-Delbrueck-Center for Molecular Medicine) (submittedVersion)
- eSpace (Curtin University) (submittedVersion)
- Funders
- U.S. Department of Defense
- Memorial Sloan-Kettering Cancer Center
- Canada's Michael Smith Genome Sciences Centre
- Canadian Breast Cancer Research Alliance
- Michael Smith Health Research BC
- Cancer Research UK
- National Institute for Health and Care Research (NF-SI-0611-10154)
- Cure Brain Cancer Foundation
- BC Cancer Foundation
- National Institutes of Health
- Imperial Experimental Cancer Medicine Centre
- BC Cancer Agency
- National Institute of General Medical Sciences (R01GM084875)
- National Institute of Environmental Health Sciences (U01ES017154)
- Congressionally Directed Medical Research Programs
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Keywords
- triple-negative breast cancer, clonal evolution, somatic mutations, copy number variation, cancer genomics, TP53 mutation, PIK3CA mutation, PTEN mutation, basal subtype, tumor progression, founder mutation, clonal heterogeneity
- MeSH terms
- Alleles, Breast Neoplasms, Clone Cells, DNA Mutational Analysis, Female, Genotype, Humans, Mutation, Reproducibility of Results, Gene Expression Regulation, Neoplastic, Point Mutation, Sequence Analysis, RNA, Disease Progression, Evolution, Molecular, Gene Expression Profiling, INDEL Mutation, DNA Copy Number Variations, Precision Medicine, High-Throughput Nucleotide Sequencing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
